Sudhir B Malla
Overview
Explore the profile of Sudhir B Malla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bull C, Byrne R, Fisher N, Corry S, Amirkhah R, Edwards J, et al.
Sci Rep
. 2024 Dec;
14(1):30202.
PMID: 39632911
Gene set enrichment analysis (GSEA) tools can identify biological insights within gene expression-based studies. Although their statistical performance has been compared, the downstream biological implications that arise when choosing between...
2.
Malla S, Byrne R, Lafarge M, Corry S, Fisher N, Tsantoulis P, et al.
Nat Genet
. 2024 Jun;
56(6):1321.
PMID: 38831011
No abstract available.
3.
Malla S, Byrne R, Lafarge M, Corry S, Fisher N, Tsantoulis P, et al.
Nat Genet
. 2024 Feb;
56(3):458-472.
PMID: 38351382
Molecular stratification using gene-level transcriptional data has identified subtypes with distinctive genotypic and phenotypic traits, as exemplified by the consensus molecular subtypes (CMS) in colorectal cancer (CRC). Here, rather than...
4.
Pun S, ONeill K, Edgar K, Gill E, Moez A, Naderi-Meshkin H, et al.
Cells
. 2023 Sep;
12(18).
PMID: 37759443
Ischaemic cardiovascular disease is associated with tissue hypoxia as a significant determinant of angiogenic dysfunction and adverse remodelling. While cord blood-derived endothelial colony-forming cells (CB-ECFCs) hold clear therapeutic potential due...
5.
Amirkhah R, Gilroy K, Malla S, Lannagan T, Byrne R, Fisher N, et al.
Br J Cancer
. 2023 Jan;
128(7):1333-1343.
PMID: 36717674
Background: Colorectal cancer (CRC) primary tumours are molecularly classified into four consensus molecular subtypes (CMS1-4). Genetically engineered mouse models aim to faithfully mimic the complexity of human cancers and, when...
6.
Fisher N, Byrne R, Leslie H, Wood C, Legrini A, Cameron A, et al.
Clin Cancer Res
. 2022 Jul;
28(18):4056-4069.
PMID: 35792866
Purpose: Precise mechanism-based gene expression signatures (GES) have been developed in appropriate in vitro and in vivo model systems, to identify important cancer-related signaling processes. However, some GESs originally developed...
7.
Corry S, McCorry A, Lannagan T, Leonard N, Fisher N, Byrne R, et al.
Gut
. 2022 Apr;
71(12):2502-2517.
PMID: 35477539
Objective: Stroma-rich tumours represent a poor prognostic subtype in stage II/III colon cancer (CC), with high relapse rates and limited response to standard adjuvant chemotherapy. Design: To address the lack...
8.
Ahmaderaghi B, Amirkhah R, Jackson J, Lannagan T, Gilroy K, Malla S, et al.
Dis Model Mech
. 2022 Feb;
15(3).
PMID: 35112706
Generation of transcriptional data has dramatically increased in the past decade, driving the development of analytical algorithms that enable interrogation of the biology underpinning the profiled samples. However, these resources...
9.
Najumudeen A, Ceteci F, Fey S, Hamm G, Steven R, Hall H, et al.
Nat Genet
. 2021 Jan;
53(1):16-26.
PMID: 33414552
Oncogenic KRAS mutations and inactivation of the APC tumor suppressor co-occur in colorectal cancer (CRC). Despite efforts to target mutant KRAS directly, most therapeutic approaches focus on downstream pathways, albeit...
10.
Malla S, Fisher D, Domingo E, Blake A, Hassanieh S, Redmond K, et al.
Clin Cancer Res
. 2020 Oct;
27(1):288-300.
PMID: 33028592
Purpose: The DNA damage immune response (DDIR) assay was developed in breast cancer based on biology associated with deficiencies in homologous recombination and Fanconi anemia pathways. A positive DDIR call...